Context Therapeutics Inc.

Context is dedicated to developing the next generation of therapies to treat solid tumors, with a primary focus on female cancers. Female cancers include breast, ovarian, and endometrial cancer. To target these cancers, we are advancing bispecific antibody (CTIM-76) and small molecule (ONA-XR) investigational medicines. CTIM-76 is an investigational anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAbs) that is intended to redirect T-cell mediated lysis toward malignant cells expressing CLDN6. ONA-XR or onapristone extended release is an investigational medicine for the treatment of ovarian, uterine (endometrial), and breast cancers. These cancers are progesterone-dependent and ONA-XR functions by blocking the progesterone receptor (PR).